Listed

Rand Capital Corp: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 7, 2019 and accepted by EDGAR at Nov 7, 2019, 08:00 ET.

Share

Management's discussion and analysis

As filed, 30,626 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and related notes included elsewhere in this report. Historical results and percentage relationships among any amounts in the consolidated financial statements are not necessarily indicative of trends in operating results for any future periods.

FORWARD LOOKING STATEMENTS

Statements included in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report that do not relate to present or historical conditions are “forward-looking statements” within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended. Additional oral or written forward-looking statements may be made by us from time to time, and forward-looking statements may be included in documents that are filed with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause our results or outcomes to differ materially from those expressed in the forward-looking statements. Forward-looking statements may include, without limitation, statements relating to our plans, strategies, objectives, expectations and intentions and are intended to be made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “forecasts,” “intends,” “possible,” “expects,” “estimates,” “anticipates,” or “plans” and similar expressions are intended to identify forward-looking statements. Among the important factors on which such statements are based are assumptions concerning the state of the United States economy and the local markets in which our portfolio companies operate, the state of the securities markets in which the securities of our portfolio companies could be traded, liquidity within the United States financial markets, and inflation. Forward-looking statements are also subject to the risks and uncertainties described under the caption “Risk Factors” contained in Part II, Item 1A of this report and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018.

There may be other factors not identified that affect the accuracy of our forward-looking statements. Further, any forward-looking statement speaks only as of the date when it is made and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time that may cause our business not to develop as we expect, and we cannot predict all of them.

Overview

We are currently an internally managed investment company that lends to and invests in small companies, often concurrently with other investors. We have elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). As a BDC, we are required to comply with certain regulatory requirements. We have historically made the majority of our investments through our wholly-owned subsidiary, Rand Capital SBIC, Inc. (“Rand SBIC”), which operates as a small business investment company (“SBIC”) and has been licensed by the U.S. Small Business Administration (“SBA”) since 2002. Rand SBIC was approved for an additional $6.0 million in new SBA leverage commitments during 2018 and has drawn down $3.0 million of that leverage as of September 30, 2019.

In January 2019, we entered into a stock purchase agreement to sell approximately 8.3 million shares of our common stock to East Asset Management, LLC (“East”) for $25 million in cash and portfolio assets, which will be income-producing instruments. Additionally, upon closing of the pending Transactions (the “Transactions”), a new entity, Rand Capital Management LLC (“RCM”) will be retained by Rand to be its investment advisor as an external management company. RCM will have the same management team that is currently at Rand. Rand’s shareholders approved all proposals related to the Transactions at a special meeting of shareholders that was held on May 16, 2019. Rand’s wholly-owned subsidiary, Rand Capital SBIC, Inc., received approval from the SBA for Rand to proceed with the pending Transaction with East. Rand expects the Transaction to close during November 2019.

Following the closing of the above-described Transactions and contingent upon meeting certain tax-related conditions, we intend to elect to become a regulated investment company (“RIC”) for U.S. federal tax purposes. This will enable the pass through of capital gains and investment income to shareholders without payment of corporate-level U.S. federal income tax by Rand.

Outlook

At the end of the third quarter of 2019, we had $9.3 million in cash and cash equivalents available for future investments and expenses, an increase of $5.3 million as compared to the end of 2018. The increase was primarily due to $4.5 million in loans repaid by two portfolio companies and $2.25 million of additional SBA leverage drawn down during the nine months ended September 30, 2019.

We believe the combination of cash on hand, proceeds from portfolio exits, SBA leverage, and prospective investment income provide sufficient capital for us to continue to add new investments to our portfolio while reinvesting in existing portfolio companies that demonstrate continued growth potential. Additionally, upon the anticipated closing of the Transactions described above, we will have additional investments in our portfolio and additional cash to invest. The following short and long-term trends provide us confidence in our ability to grow Rand:

  • We expect that well run businesses will require capital to grow and should be able to compete effectively given eager reception of new technologies and service concepts, regardless of the macroeconomic environment.
  • We continue to manage risk by investing with other investors, when possible.
  • We are involved with the governance and management of a majority of our portfolio companies, which enables us to support their operating and marketing efforts and facilitate their growth.
  • As our portfolio expands, we are able to better leverage our infrastructure.
  • We believe the anticipated receipt of cash and portfolio assets from East, as well as the establishment of RCM as an external management company, will broaden our potential pipeline of investment opportunities in order to build our portfolio and grow further. Strategically, we expect to advance our efforts to increase our income-producing investments that can support a regular cash dividend for shareholders and complement our equity investments that drive capital appreciation.
  • We have sufficient cash to invest in new opportunities and to repurchase shares. At period end, we had authorization to repurchase an additional 1,000,000 shares of our common stock.

Critical Accounting Policies

We prepare our consolidated financial statements in accordance with United States generally accepted accounting principles (GAAP), which require the use of estimates and assumptions that affect the reported amounts of assets and liabilities. A summary of our critical accounting policies can be found in our Annual Report on Form 10-K for the year ended December 31, 2018 under Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Financial Condition

Overview: September 30, 2019 December 31, 2018 (Decrease) Increase % (Decrease) Increase
Total assets $38,661,339 $40,521,724 ($ 1,860,385) (4.6%)
Total liabilities 10,908,174 8,997,537 1,910,637 21.2%
Net assets $27,753,165 $31,524,187 ($ 3,771,022) (12.0%)

Net asset value per share (NAV) was $4.39 at September 30, 2019 and $4.99 at December 31, 2018.

Our gross outstanding SBA debentures at September 30, 2019 were $11,000,000 and will mature from 2022 through 2029. Cash and cash equivalents approximated 33% of net assets at September 30, 2019, as compared to 13% at December 31, 2018.

Composition of Our Investment Portfolio

Our financial condition is dependent on the success of our portfolio holdings. We have invested substantially all of our assets in small to medium-sized companies. The following summarizes our investment portfolio at the dates indicated.

September 30, 2019 December 31, 2018 (Decrease) % Decrease
Investments, at cost $34,609,818 $38,292,143 ($ 3,682,325) (9.6%)
Unrealized depreciation, net (7,822,620) (3,625,339) (4,197,281) 115.8%
Investments at fair value $26,787,198 $34,666,804 ($ 7,879,606) (22.7%)

Our total investments at fair value, as estimated by management and approved by our Board of Directors, approximated 97% of net assets at September 30, 2019 versus 110% of net assets at December 31, 2018.

The change in investments during the nine months ended September 30, 2019, at cost, is comprised of the following:

New investments: Cost Increase (Decrease)
Tilson Technology Management, Inc. (Tilson) $500,012
Genicon Inc. (Genicon) 250,000
KnowledgeVision Systems, Inc. (Knowledgevision) 150,000
Advantage 24/7 LLC (Advantage 24/7) 140,000
Total of new investments 1,040,012
Other changes to investments:
Genicon interest conversion and OID amortization 276,961
Empire Genomics, LLC (Empire Genomics) capitalized fee income and interest conversion 75,481
Microcision LLC (Microcision) interest conversion 14,536
GoNoodle, Inc. (GoNoodle) interest conversion 7,817
Total of other changes to investments 374,795
Investments repaid, sold, liquidated or converted:
eHealth Global Technologies, Inc. (eHealth) loan repayment (3,500,000)
Tilson loan repayment (1,000,000)
SOMS Technologies, LLC (SOMS) realized loss (472,632)
Advantage 24/7 investment conversion and loan repayment (124,500)
Total of investments repaid, sold, liquidated or converted (5,097,132)
Net change in investments, at cost ($ 3,682,325)

37

Results of Operations

Our principal investment objective is to achieve long-term capital appreciation on our equity investments while maintaining a current cash flow from our debt instruments and pass-through equity instruments to fund expenses. Therefore, we invest in a variety of financial instruments to provide a current return on a portion of the investment portfolio.

Comparison of the three months ended September 30, 2019 to the three months ended September 30, 2018

Investment Income

Three months ended September 30, 2019 Three months ended September 30, 2018 (Decrease) Increase % (Decrease) Increase
Interest from portfolio companies $328,103 $450,289 ($ 122,186) (27.1%)
Interest from other investments 36,797 7,872 28,925 367.4%
Dividend and other investment income 65,996 48,856 17,140 35.1%
Fee income 6,459 155,285 (148,826) (95.8%)
Total investment income $437,355 $662,302 ($ 224,947) (34.0%)

The total investment income that was received on a current basis for the three months ended September 30, 2019 and 2018 was received from ten portfolio companies.

Interest from portfolio companies – Interest from portfolio companies decreased during the three months ended September 30, 2019 versus the same period in 2018 due to the fact that the debt instrument from eHealth Global Technologies, Inc. (eHealth) was repaid during the first quarter of 2019. In addition, during the third quarter of 2018, loans to Empire Genomics were modified and resulted in the recording of interest that had previously not been accrued of approximately $91,000. The following investments are on non-accrual status: BeetnPath, LLC (Beetnpath), G-TEC Natural Gas Systems (G-Tec) and a portion of the Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balances.

Interest from other investments - The increase in interest from other investments is primarily due to higher interest rates and higher average cash balance during the three months ended September 30, 2019 versus the same period in 2018.

Dividend and other investment income - Dividend income is comprised of cash distributions from limited liability companies (LLCs) and corporations in which we have invested. Our investment agreements with certain LLCs require those LLCs to distribute funds to us for payment of income taxes on our allocable share of the LLC’s profits. These portfolio companies may also elect to make additional discretionary distributions. Dividend income will fluctuate based upon the profitability of these LLCs and corporations and the timing of the distributions or the impact of new investments or divestitures. The dividend distributions for the respective periods were:

Three months ended September 30, 2019 Three months ended September 30, 2018
Carolina Skiff LLC (Carolina Skiff) $52,871 $39,169
Tilson Technology Management, Inc. (Tilson) 13,125 9,687
Total dividend and other investment income $65,996 $48,856

Fee income - Fee income generally consists of the revenue associated with the amortization of financing fees charged to the portfolio companies upon successful closing of SBIC financings, income from portfolio company board attendance fees and other miscellaneous fees. The financing fees are amortized ratably over the life of the instrument associated with the fees. The unamortized fees are carried on the Consolidated Statement of Financial Position in the line item “Deferred revenue.”

The income associated with the amortization of financing fees was $6,459 and $12,939 for the three months ended September 30, 2019 and 2018, respectively. In addition, we recorded a one-time debt modification fee of approximately $142,000 during the three month ended September 30, 2018. We charged the fee to Empire Genomics and the fee was capitalized into the Empire Genomics loan balances as part of the debt modification.

Expenses

Three months ended September 30, 2019 Three months ended September 30, 2018 Increase % Increase
Total expenses $530,539 $447,800 $82,739 18.5%

Expenses predominately consist of interest expense on outstanding SBA borrowings, compensation expense, and general and administrative expenses, including stockholders and office operating expenses and professional fees.

The increase in expenses during the three months ended September 30, 2019 versus the same period in 2018 was primarily caused by a 79%, or $37,973, increase in stockholders expense and a 21%, or $16,623, increase in interest expense. We incurred additional stockholders expense related to the aforementioned Transactions with East Asset Management and the regulatory procedures that are required to effect such Transactions. Our interest expense increased due to higher outstanding SBA debt.

Net Realized Loss on Investments

Three months ended September 30, 2019 Three months ended September 30, 2018 Change
Realized loss on investments before income taxes $— ($ 1,125,673) ($ 1,125,673)

During the three months ended September 30, 2018, we recognized a loss on our investment in Intrinsiq Material, Inc. (Intrinsiq) when the company was sold and we did not receive any proceeds. There were no realized gains or losses during the three months ended September 30, 2019.

Change in Unrealized Depreciation of Investments

Three months ended September 30, 2019 Three months ended September 30, 2018 Change
Change in unrealized depreciation of investments before income taxes ($ 3,597,129) $475,802 ($ 4,072,931)

The change in unrealized depreciation, before income taxes, for the three months ended September 30, 2019 was comprised of the following:

Three months ended September 30, 2019
Rheonix, Inc. (Rheonix) ($ 1,500,000)
Genicon, Inc. (Genicon) (1,447,467)
Empire Genomics, LLC (Empire Genomics) (249,661)
KnowledgeVision Systems, Inc. (KnowledgeVision) (200,001)
SciAps, Inc. (Sciaps) (200,000)
Total change in net unrealized depreciation of investments, before income taxes ($ 3,597,129)

39

The valuations of our investments in Empire Genomics, Genicon, KnowledgeVision, Rheonix and Sciaps were decreased after we reviewed each of the portfolio company’s operations, commercial progress against their business plan, and past and projected financial condition and determined that a valuation adjustment was necessary. Some of these decreases in value may be recoverable following the completion of their respective future financings.

The change in unrealized depreciation, before income taxes, for the three months ended September 30, 2018 was comprised of the following:

Three months ended September 30, 2018
Empire Genomics, LLC (Empire Genomics) ($ 249,871)
Intrinsiq Material, Inc. (Intrinsiq) realized loss 725,673
Total change in net unrealized depreciation of investments, before income taxes $475,802

The valuation of our investment in Empire Genomics was decreased after we reviewed the portfolio company’s operations and current and projected financial condition, after the debt modification, and determined that a valuation adjustment was necessary.

Intrinsiq was sold during the third quarter of 2018 and a realized loss was recorded.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

Net Increase (Decrease) in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is “net increase (decrease) in net assets from operations” on our consolidated statements of operations. For the three months ended September 30, 2019 and 2018, the net decrease in net assets from operations was ($2,878,888) and ($179,302), respectively.

Comparison of the nine months ended September 30, 2019 to the nine months ended September 30, 2018

Investment Income

Nine months ended September 30, 2019 Nine months ended September 30, 2018 (Decrease) Increase % (Decrease) Increase
Interest from portfolio companies $1,049,557 $1,063,337 ($ 13,780) (1.3%)
Interest from other investments 108,146 20,717 87,429 422.0%
Dividend and other investment income 307,681 181,963 125,718 69.1%
Fee income 274,387 172,612 101,775 58.9%
Total investment income $1,739,771 $1,438,629 $301,142 20.9%

Interest from portfolio companies – Interest from portfolio companies was approximately the same during the nine months ended September 30, 2019 when compared to the same nine month period in 2018.

The following investments are on non-accrual status: BeetNPath, LLC (Beetnpath), G-TEC Natural Gas Systems (G-Tec) and a portion of the Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balances.

Interest from other investments—The increase in interest from other investments is primarily due to higher interest rates and higher average cash balance during the nine months ended September 30, 2019 versus the same period in 2018.

Dividend and other investment income—Dividend income is comprised of cash distributions from limited liability companies (LLCs) and corporations in which we have invested. Our investment agreements with certain LLCs require those LLCs to distribute funds to us for payment of income taxes on our allocable share of the LLC’s profits. These portfolio companies may also elect to make additional discretionary distributions. Dividend income will fluctuate based upon the profitability of these LLCs and corporations and the timing of the distributions or the impact of new investments or divestitures. The dividend distributions for the respective periods were:

Nine months ended September 30, 2019 Nine months ended September 30, 2018
Knoa Software, Inc. (Knoa) $193,934 $—
Carolina Skiff LLC (Carolina Skiff) 76,914 119,433
Tilson Technology Management, Inc. (Tilson) 36,833 29,063
New Monarch Machine Tool, Inc. (New Monarch) — 27,409
Empire Genomics LLC (Empire Genomics) — 6,058
Total dividend and other investment income $307,681 $181,963

Fee income—Fee income generally consists of the revenue associated with the amortization of financing fees charged to the portfolio companies upon successful closing of SBIC financings, income from portfolio company board attendance fees and other miscellaneous fees. The financing fees are amortized ratably over the life of the instrument associated with the fees. The unamortized fees are carried on the balance sheet under the line item “Deferred revenue.”

The income associated with the amortization of financing fees was $48,887 and $28,266 for the nine months ended September 30, 2019 and 2018, respectively. During the nine months ended September 30, 2019 we recognized a one-time fee of $225,000 in conjunction with the repayment of the eHealth loan instrument. During the nine months ended September 30, 2018 we recorded a one-time debt modification fee of approximately $142,000 that was charged to Empire Genomics and capitalized into the Empire Genomics loan balance. The board fees were $500 and $2,000 for the nine months ended September 30, 2019 and 2018, respectively.

Expenses

Nine months ended September 30, 2019 Nine months ended September 30, 2018 Increase % Increase
Total expenses $2,044,351 $1,510,034 $534,317 35.4%

Expenses predominately consist of interest expense on outstanding SBA borrowings, compensation expense, and general and administrative expenses, including stockholder and office operating expenses and professional fees.

The increase in expenses during the nine months ended September 30, 2019 versus the same period in 2018 was primarily caused by a 164%, or $289,666, increase in shareholder expense and an 84%, or $186,086, increase in professional fees. Shareholder expense and professional fees were higher during the nine months ended September 30, 2019 because we incurred expenses in connection with aforementioned Transactions with East Asset Management, the special shareholder meeting held in May 2019 and the regulatory procedures that are required to effect such transactions. These expenses also included external shareholder, legal, tax consulting and other advisory expenses to support the complex regulatory environment in which we operate.

In addition, we deferred $266,000 in stock issuance costs attributable to the Transactions. These expenses are intended to be offset against the equity capital raise when the Transactions close, or expensed if the Transactions are not completed. The deferred expenses are included on our Consolidated Statement of Financial Position at September 30, 2019 in the line item “Other assets.”

Net Realized Loss on Investments

Nine months ended September 30, 2019 Nine months ended September 30, 2018 Change
Realized loss on investments before income taxes ($ 392,239) ($ 1,125,673) $733,434

During the nine months ended September 30, 2019, we recognized a realized loss on our investment in SOMS Technologies, LLC after the company ceased doing business and a $40,500 gain on our investment in Advantage 24/7 LLC after the company converted their equity into a debt instrument. In addition, we received a final proceeds distribution of $39,893 from Gemcor II, LLC, a portfolio company we exited in 2016.

During the nine months ended September 30, 2018, we recognized a loss on our investment in Intrinsiq Material, Inc. (Intrinsiq) when the company was sold and we did not receive any proceeds.

Change in Unrealized Depreciation of Investments

Nine months ended September 30, 2019 Nine months ended September 30, 2018 Change
Change in unrealized depreciation of investments before income taxes ($ 4,197,281) ($ 732,128) ($ 3,465,153)

The change in unrealized depreciation, before income taxes, for the nine months ended September 30, 2019 was comprised of the following:

Nine months ended September 30, 2019
Genicon ($ 2,200,047)
Rheonix (1,500,000)
SocialFlow, Inc. (Socialflow) (1,071,300)
Sciaps (585,000)
BeetNPath, LLC (Beetnpath) (523,904)
Empire Genomics (249,661)
KnowledgeVision (200,001)
Mercantile Adjustment Bureau, LLC (Mercantile) (200,000)
SOMS Technologies, LLC realized loss 472,632
Tilson Technology Management, Inc. (Tilson) 1,860,000
Total change in net unrealized depreciation of investments before income taxes ($ 4,197,281)

The valuations of our investments in Beetnpath, Empire Genomics, KnowledgeVision, Mercantile, Rheonix, Sciaps, and Socialflow were decreased after we reviewed each of the portfolio company’s operations, commercial progress against their business plan, and past and projected financial condition and determined that a valuation adjustment was necessary.

Our valuation of Genicon was decreased due to a recent round of financing and after a review of their financial condition.

In accordance with our valuation policy, we increased the value of our holdings in Tilson based on a significant equity financing during the first quarter of 2019 with a sophisticated new non-strategic outside investor at a higher valuation than their prior financing round valuation.

We recognized a realized loss on our investment in SOMS during the nine months ended September 30, 2019.

The change in unrealized depreciation, before income taxes, for the nine months ended September 30, 2018 was comprised of the following:

Nine months ended September 30, 2018
Empire Genomics, LLC (Empire Genomics) ($ 901,360)
SOMS Technologies, LLC (SOMS) (498,348)
First Wave Products Group (First Wave) (250,000)
GiveGab, Inc. (Givegab) 191,907
Intrinsiq Material, Inc. (Intrinsiq) realized loss 725,673
Total change in net unrealized depreciation of investments before income taxes ($ 732,128)

The valuations of our investments in Empire Genomics and SOMS were decreased after we reviewed each of the portfolio company’s operations and current and projected financial condition and determined that a valuation adjustment was necessary.

Our valuation of First Wave was decreased to reflect an anticipated round of financing that was completed in the fourth quarter of 2018.

Givegab’s value was increased to the cost basis of the investment after a financial analysis of the portfolio company indicating continued improved performance. Intrinsiq was sold during the third quarter of 2018 and a realized loss was recorded.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

Net Increase (Decrease) in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is “net increase (decrease) in net assets from operations” on our consolidated statements of operations. For the nine months ended September 30, 2019 and 2018, the net decrease in net assets from operations was ($3,771,022) and ($1,331,009), respectively.

Liquidity and Capital Resources

Historically, our principal objective has been to achieve capital appreciation. Therefore, a significant portion of the investment portfolio is structured to maximize the potential for capital appreciation and may provide little or no current yield in the form of dividends or interest payments. As discussed above, on closing of the Transactions contemplated by the stock purchase agreement with East, we expect to receive interest bearing investments and subsequently to position the portfolio to earn a current yield.

As of September 30, 2019, our total liquidity consisted of approximately $9.3 million in cash and cash equivalents on hand and the availability of $3.0 million under our SBA leverage commitment.

Net cash used by operating activities has averaged approximately $1.6 million over the last three years. The average cash used for investment in portfolio companies over the last three years was approximately $2.1 million. Our cash flow from operations may fluctuate based on the timing of the receipt of dividend income and realized gains and the associated income taxes paid. We will generally use cash to fund our operating expenses and also to invest in companies, as we seek to build our portfolio utilizing our available cash and proceeds from liquidations of portfolio investments. We anticipate that we will continue to exit investments. However, the timing of liquidation events within the portfolio is difficult to project with any certainty. As of September 30, 2019, we had the availability to borrow an additional $3.0 million from the SBA. Starting in 2022, our SBA debt begins to reach maturity, and this will require us to identify sources of future funding if liquidation of investments is not sufficient to fund operations and repay the SBA debt obligation.

We believe that the cash on hand, the scheduled interest payments on our portfolio investments and our SBA leverage commitment will be sufficient to meet our cash needs for the next twelve months. We continue to seek potential exits from portfolio companies to increase the amount of liquidity available for new investments, operating activities and future SBA debenture repayment obligations.

Market risk

As filed, 1,789 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our investment activities contain elements of risk. Our investment portfolio consists of equity and debt securities in private companies and is subject to valuation risk. Because there is typically no public market for the equity and debt securities in which we invest, the valuation of the equity interests in the portfolio is stated at “fair value” as determined in good faith by our management and approved by our Board of Directors. This is in accordance with our investment valuation policy (see the discussion of valuation policy contained in “Note 3. Investments” in the consolidated financial statements contained in Item 1 of this report, which is hereby incorporated herein by reference.) In the absence of readily ascertainable market values, the estimated value of the portfolio may differ significantly from the values that would be placed on the portfolio if a ready market for the investments existed. Any changes in valuation are recorded on the consolidated statement of operations as “Net change in unrealized depreciation on investments.”

At times, a portion of our portfolio may include marketable securities traded in the over-the-counter market. In addition, there may be a portion of the portfolio for which no regular trading market exists. In order to realize the full value of a security, the market must trade in an orderly fashion or a willing purchaser must be available when a sale is to be made. Should an economic or other event occur that would not allow markets to trade in an orderly fashion, we may not be able to realize the fair value of our marketable investments or other investments in a timely manner.

As of September 30, 2019, we did not have any off-balance sheet arrangements or hedging or similar derivative financial instrument investments.

Controls and procedures

As filed, 1,373 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures. The Corporation maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that this information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Chief Executive Officer and the Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of the Corporation’s disclosure controls and procedures as of September 30, 2019. Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that the Corporation’s controls and procedures were effective as of September 30, 2019.

Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting during the Corporation’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Corporation’s internal control over financial reporting.

PART II.

OTHER INFORMATION

Source: SEC EDGAR, the filing index for accession 0001193125-19-286651. Last ingested by Listed: Nov 4, 2026, 08:48 ET. Listed shows no prices and gives no investment advice.